EPILEPSY FOUNDATION for EPILEPSY FOUNDATION
What was lobbied
2 issue areas, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
-H.R. 5376 Inflation Reduction Act, support addressing affordability of health insurance premiums; creating an out-of-pocket cap in Medicare Part D with smoothing mechanism; and barring the use of discriminatory quality-adjusted life year (QALY) in prescription drug legislation. -S. 464/H.R. 2163, Safe Step Act, support passage. -HR 8454 Medical Marijuana and Cannabidiol Research Expansion Act, support passage. -Identify and make recommendations on improvements to federal law for access to medical cannabis and medical cannabis products. -H.R. 5435, BRAIN Act, S. 3427, Neuroscience Center of Excellence Act and H.R. 6000, Cures 2.0 Act, support creation of a Neuroscience Center of Excellence at the FDA that is patient-focused and related necessary appropriations. -S. 4348 Food and Drug Administration Safety and Landmark Advancements Act of 2022 / H.R. 7667 Food and Drug Amendments Act of 2022, ensure that any new regulation of dietary supplements protects access to CBD, support amendment to ban use of certain electric shock devices, support provisions regarding diverse enrollment in clinical trials, support provisions to support orphan drug development
| Lobbyist | Covered position, as disclosed |
|---|---|
| TYLER BECK New | — |
| RACHEL PATTERSON | — |
| LAURA WEIDNER | — |
Budget/Appropriations BUD
-Labor, Health and Human Services, Education and Related Agencies Appropriations Act, 2023, support funding for epilepsy programs and research including $13 million for the CDCs Epilepsy program, $49 billion for the NIH, $5 million for the National Neurological Conditions Surveillance System and increased funding for the Social Security Administration. -Military Construction, Veterans Affairs, and Related Agencies Appropriations Act, 2023, support $19 million for the VA Epilepsy Centers of Excellence. -Agriculture, Rural Development, Food and Drug Administration and Related Agencies Appropriations Act, 2023, support $3.653 billion for the Food & Drug Administrations BA. -Defense Appropriations Act, 2023, support robust funding for epilepsy-related research through the Congressionally Directed Medical Research Programs. -H.R. 6833 Continuing Appropriations and Ukraine Supplemental Appropriations Act, support passage to ensure federal funding for programs and research important to the epilepsy community through December 16, 2022.
| Lobbyist | Covered position, as disclosed |
|---|---|
| TYLER BECK New | — |
| RACHEL PATTERSON | — |
| LAURA WEIDNER | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.